Neoadjuvant treatment in resectable pancreatic cancer: Why is upfront surgery so hard to be beaten?

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 9

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-3)

Sum=174

Publishing Process of This Article

Item

Count

Browse

Download

Sum=91

Sep 24, 2025 (publication date) through Oct 27, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Sep 24, 2025; 16(9): 108955
Published online Sep 24, 2025. doi: 10.5306/wjco.v16.i9.108955

Figure 1 Multimodal approach for curative-intent treatment of localized pancreas cancer. Created in BioRender (Supplementary material). Araujo R (2025), https://BioRender.com/hptgk9a.

Citation: Uson Junior PLS, Kadakia KC, Araujo RLC. Neoadjuvant treatment in resectable pancreatic cancer: Why is upfront surgery so hard to be beaten? World J Clin Oncol 2025; 16(9): 108955
URL: https://www.wjgnet.com/2218-4333/full/v16/i9/108955.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i9.108955